Yes, for most people. 96% of 27 people who reported on Metformin for blood sugar say it improved. 4% noticed no change and 0% say it got worse. That is above the typical result for blood sugar (87% across 3 options).
Ranked #1 of 3 for blood sugar.
“Berberine has done zero for my pre diabetic glucose levels or weight. Metformin has and I changed nothing else.”
“Terrible side effects for me stomach wise and didnt particularly impact my blood sugar either...A1c went from 5.9 to 5.6 on metformin.”
“Been on it for 17 years. Only recognizable benefit is to reduce my blood sugar. No side effects noted, dosage for 14 years has been 2,000 mg a day, split half in morning and half in evening.”
“My doctor prescribed it for life extension purposes / increase insulin sensitivity. The main reason I stopped to was that it reduced exercise performance.”
Conclusion: In diabetic patients at low cardiovascular risk, no treatment differs from placebo for vascular outcomes. In patients at increased cardiovascular risk receiving metformin-based background therapy, specific GLP-1 RAs and SGLT-2 inhibitors have a favorable effect on certain cardiovascular outcomes.
Conclusion: The evidence supports metformin as first-line therapy for type 2 diabetes, given its relative safety and beneficial effects on hemoglobin A1c, weight, and cardiovascular mortality (compared with sulfonylureas). On the basis of less evidence, results for add-on therapies to metformin were similar to those for monotherapies.
Conclusion: Metformin may be associated with a decreased risk of many cancer types, but high heterogeneity and risk of publication bias limit confidence in these results. Additional studies in populations without diabetes are needed to better understand the utility of metformin in cancer prevention.
Information only — not medical advice. How we count